Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Current Leases: 2023-2025

Historic Current Leases for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $998,000.

  • BioLineRx's Current Leases rose 489.84% to $998,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $998,000, marking a year-over-year increase of 489.84%. This contributed to the annual value of $522,000 for FY2024, which is 1.14% down from last year.
  • According to the latest figures from Q2 2025, BioLineRx's Current Leases is $998,000, which was up 1.32% from $985,000 recorded in Q1 2025.
  • BioLineRx's 5-year Current Leases high stood at $1.3 million for Q3 2024, and its period low was -$323,000 during Q3 2023.
  • In the last 3 years, BioLineRx's Current Leases had a median value of $236,500 in 2023 and averaged $338,600.
  • As far as peak fluctuations go, BioLineRx's Current Leases plummeted by 163.27% in 2024, and later soared by 863.57% in 2025.
  • Over the past 3 years, BioLineRx's Current Leases (Quarterly) stood at $528,000 in 2023, then decreased by 1.14% to $522,000 in 2024, then soared by 489.84% to $998,000 in 2025.
  • Its Current Leases was $998,000 in Q2 2025, compared to $985,000 in Q1 2025 and $522,000 in Q4 2024.